Xilio Therapeutics (XLO) director receives grant of 5,000 stock options

Rhea-AI Filing Summary

Xilio Therapeutics director Robert W. Ross received a stock option grant covering 5,000 shares of common stock. The option has an exercise price of $7.99 per share and expires on June 10, 2036. It will vest in full on the earlier of June 11, 2027 or the company’s next annual stockholder meeting, assuming he remains in service. This is a compensation-related award, not an open-market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ROSS ROBERT W.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	5,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 5,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 5,000 shares Exercise price: $7.99 per share Expiration date: June 10, 2036 +2 more

5 metrics

Option grant size 5,000 shares Stock option covering common stock granted to director

Exercise price $7.99 per share Strike price for the 5,000-share stock option

Expiration date June 10, 2036 Final date the option can be exercised

Post-grant option holdings 5,000 options Total stock options held following this grant

Vesting date trigger June 11, 2027 or next annual meeting Earlier date for 100% vesting, subject to continued service

Key Terms

Stock Option (right to buy), exercise price, vesting, annual meeting of stockholders, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "7.9900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"will vest as to 100% of the shares underlying the option"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders following the grant date"

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROSS ROBERT W.

(Last) (First) (Middle)

828 WINTER STREET

SUITE 300

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xilio Therapeutics, Inc. [ XLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.99	06/11/2026		A		5,000		(1)	06/10/2036	Common Stock	5,000	$0	5,000	D

Explanation of Responses:

1. The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.

	/s/ Christopher Frankenfield, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Xilio Therapeutics (XLO) report for Robert W. Ross?

Xilio Therapeutics reported a grant of stock options to director Robert W. Ross for 5,000 shares. The options are compensation, not a market purchase, and give him the right to buy common stock at a fixed exercise price.

How many Xilio Therapeutics (XLO) shares are covered by Ross’s new stock options?

The new stock option grant to Robert W. Ross covers 5,000 shares of Xilio Therapeutics common stock. These options provide potential future ownership if he chooses to exercise them at the stated $7.99 per share exercise price.

What is the exercise price and expiration date of Robert W. Ross’s Xilio (XLO) options?

The stock options granted to Robert W. Ross have an exercise price of $7.99 per share and expire on June 10, 2036. He can choose to exercise them any time after vesting and before this expiration date, subject to plan terms.

When do Robert W. Ross’s Xilio Therapeutics (XLO) stock options vest?

Ross’s stock options will vest 100% on the earlier of June 11, 2027 or Xilio Therapeutics’ next annual meeting of stockholders after the grant date. Vesting is conditioned on his continued service with the company through the applicable vesting date.

Is Robert W. Ross’s Form 4 transaction in Xilio (XLO) a stock purchase or sale?

The Form 4 reflects a grant of stock options, not a direct stock purchase or sale. It is categorized as a grant or award acquisition, meaning he received options as compensation rather than trading shares in the open market.